Your quote SJ, " One last note, I am glad to see that severe is also being pursued. While it may not be as promising as critical, it is likely better than most other treatment options currently available, may keep some from advancing to critical (real life impacts) and if it shows even clinical significant results, will likely be used by treating physicians and increase sales exponentially when the day comes."

Not only that above re:severe population but just think if they save people from going into Long haulers syndrome, and they keep a record of how many still have LH after their 4 doses, ( I hope they use 4 doses), I sure would like to know that statistic. IMO, there will be very few of them especially after 4 doses. I also wish they would have taken records of those given Leronlimab in cd-10, cd-12 to know who many progressed to LH status and how many on our drug got Covid on the HIV trials. To me, this is very important to know going forward as we don't know prior to this Brazil trial of 2 important arms, critical/severe. Inspiring minds want to know as it will show the world that Leronlimab in 80% (guessing) of them will not get LH syndrom or PASC - GLTU SJ and glad to see you here

HCIT or over there ahab333 where I don't post any longer, just read once in a while